<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02067390</url>
  </required_header>
  <id_info>
    <org_study_id>STU00075251</org_study_id>
    <nct_id>NCT02067390</nct_id>
  </id_info>
  <brief_title>Urinary KIM-1 After Vancomycin or Linezolid Administration</brief_title>
  <official_title>Novel Urinary Biomarkers in the Detection of Vancomycin Associated Renal Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Midwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Midwestern University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute renal injury is a common complication of critical illness. Drug induced renal insult&#xD;
      compounds the degree of injury in many patients, and a great deal of research has focused on&#xD;
      prevention of this complication. Traditional biomarkers of renal injury like serum creatinine&#xD;
      and blood urea nitrogen content fail to consistently predict harm among patients at risk.&#xD;
      Kidney Injury Molecule 1 (KIM-1) will be studied as a biomarker of renal injury.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      see above&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow enrollment&#xD;
  </why_stopped>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">May 2019</completion_date>
  <primary_completion_date type="Actual">May 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Urinary KIM-1 concentrations</measure>
    <time_frame>Urinary levels from day -1 to day +5, clinical outcomes and variables followed for duration of hospitalization</time_frame>
    <description>Urinary KIM-1 concentrations will be compared between patients receiving vancomycin and linezolid</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">5</enrollment>
  <condition>Acute Kidney Injury</condition>
  <arm_group>
    <arm_group_label>Vancomycin</arm_group_label>
    <description>Vancomycin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Linezolid</arm_group_label>
    <description>Linezolid</description>
  </arm_group>
  <biospec_retention>None Retained</biospec_retention>
  <biospec_descr>
    <textblock>
      urine&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Critically/Terminally Ill (ER, ICU)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Eligible patients are male or female adults ≥18 years of age with an expected hospital&#xD;
             stay of at least 48 hours.&#xD;
&#xD;
          -  Eligible patients are already prescribed intravenous vancomycin or linezolid per their&#xD;
             primary care providers as a standard of care and dosed in manner that is consistent&#xD;
             with current institutional practices. Receipt of these antibiotics is not&#xD;
             investigational.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Exclusion criteria will include patients who have stage 3or greater Chronic Kidney&#xD;
             Disease or who have acute kidney injury prior to the start of intravenous vancomycin&#xD;
             therapy, patients that only receive one dose of IV vancomycin or linezolid in total,&#xD;
             as well as patients with potentially altered pharmacokinetic parameters (pregnant&#xD;
             patients, burn patients, and those that are morbidly obese (BMI ≥ 40 kg/m2).&#xD;
&#xD;
          -  Additionally, patients will be excluded if they are to receive more than 1 concurrent&#xD;
             nephrotoxic medication within the prior 72 hours, have received intravenous contrast&#xD;
             within 120 hours before randomization, exhibit baseline hematuria, or baseline&#xD;
             proteinuria.&#xD;
&#xD;
          -  A list of concurrent nephrotoxins that would exclude patients from the study is&#xD;
             provided in Appendix C.&#xD;
&#xD;
          -  Age Range: ≥18 years of age, if age &gt; 90 will report as &gt; 90 years&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc H Scheetz, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern Memorial Hospital / Midwestern University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 13, 2014</study_first_submitted>
  <study_first_submitted_qc>February 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2014</study_first_posted>
  <last_update_submitted>February 18, 2020</last_update_submitted>
  <last_update_submitted_qc>February 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Midwestern University</investigator_affiliation>
    <investigator_full_name>Marc Scheetz</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Kidney Injury</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

